{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:23:59Z","timestamp":1773246239706,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.tips.2012.06.006","type":"journal-article","created":{"date-parts":[[2012,7,16]],"date-time":"2012-07-16T17:16:15Z","timestamp":1342458975000},"page":"515-521","source":"Crossref","is-referenced-by-count":34,"title":["From antipsychotic to anti-schizophrenia drugs: role of animal models"],"prefix":"10.1016","volume":"33","author":[{"given":"Mark A.","family":"Geyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berend","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian","family":"Jo\u00ebls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9 S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2012.06.006_bib0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.31887\/DCNS.2006.8.3\/tban","article-title":"The role of serendipity in drug discovery","volume":"8","author":"Ban","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.tips.2012.06.006_bib0010","first-page":"126","article-title":"\u00c9tude exp\u00e9rimentale du syndrome d\u2019irritation et application clinique \u00e0 la maladie post-traumatique","volume":"4","author":"Laborit","year":"1949","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.tips.2012.06.006_bib0015","first-page":"37","article-title":"Un nouveau stabilisateur v\u00e9g\u00e9tative (le 4560 RP)","volume":"60","author":"Laborit","year":"1952","journal-title":"Presse M\u00e9d."},{"key":"10.1016\/j.tips.2012.06.006_bib0020","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.tips.2012.06.006_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2012.06.006_bib0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0035","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0040","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0006-3223(01)01251-3","article-title":"Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient","volume":"50","author":"Kapur","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0045","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2012.06.006_bib0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","article-title":"Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia","volume":"122","author":"Young","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2012.06.006_bib0055","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.molmed.2011.08.004","article-title":"Targeting glutamate synapses in schizophrenia","volume":"17","author":"Field","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.tips.2012.06.006_bib0060","doi-asserted-by":"crossref","first-page":"102mr3","DOI":"10.1126\/scitranslmed.3002917","article-title":"Translational neuroscience of schizophrenia: seeking a meeting of minds between mouse and man","volume":"3","author":"Kas","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2012.06.006_bib0065","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1176\/ajp.151.10.1409","article-title":"One hundred years of schizophrenia: a meta-analysis of the outcome literature","volume":"151","author":"Hegarty","year":"1994","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0070","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/archgenpsychiatry.2010.69","article-title":"Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia","volume":"67","author":"Owen","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2009.09040574","article-title":"Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study","volume":"167","author":"Reichenberg","year":"2010","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0080","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/oxfordjournals.schbul.a006949","article-title":"School performance as a premorbid marker for schizophrenia: a twin study","volume":"28","author":"van Oel","year":"2002","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tips.2012.06.006_bib0085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.309.6956.699","article-title":"Childhood antecedents of schizophrenia and affective illness: a social adjustment at ages 7 and 11","volume":"309","author":"Done","year":"1994","journal-title":"Br. Med. J."},{"key":"10.1016\/j.tips.2012.06.006_bib0090","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/sj.mp.4001558","article-title":"Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence","volume":"10","author":"Harrison","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/schbul\/sbm168","article-title":"What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia","volume":"34","author":"Hulshoff Pol","year":"2008","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tips.2012.06.006_bib0100","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/archgenpsychiatry.2011.88","article-title":"Changes in cortical thickness during the course of illness in schizophrenia","volume":"68","author":"van Haren","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0105","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: the future path for animal models","volume":"34","author":"Markou","year":"2009","journal-title":"Neuropsychopharmacol. Rev."},{"key":"10.1016\/j.tips.2012.06.006_bib0110","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2012.06.006_bib0115","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0091-3057(83)90409-4","article-title":"Control of behavior by intravenous nicotine injections in human subjects","volume":"19","author":"Henningfield","year":"1983","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2012.06.006_bib0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2012.06.006_bib0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/34413","article-title":"Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine","volume":"391","author":"Picciotto","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tips.2012.06.006_bib0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature03694","article-title":"Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors","volume":"436","author":"Maskos","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tips.2012.06.006_bib0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00213-009-1739-5","article-title":"The \u03b14\u03b22 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats","volume":"208","author":"O\u2019Connor","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2012.06.006_bib0140","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.tips.2007.05.003","article-title":"Rationale, pharmacology and clinical efficacy of partial agonists of \u03b14\u03b22 nACh receptors for smoking cessation","volume":"28","author":"Rollema","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2012.06.006_bib0145","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/npp.2010.88","article-title":"Glutamate receptors in extinction and extinction-based therapies for psychiatric illness","volume":"36","author":"Myers","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2012.06.006_bib0150","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","article-title":"Facilitation of conditioned fear extinction by systemic administration of D-cycloserine as assessed with fear-potentiated startle in rats","volume":"22","author":"Walker","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2012.06.006_bib0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2006.03.084","article-title":"Effects of D-cycloserine on extinction: translation from preclinical to clinical work","volume":"60","author":"Davis","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/7854_2009_10","article-title":"Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder","volume":"2","author":"Choi","year":"2009","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.tips.2012.06.006_bib0165","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0170","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","article-title":"A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy","volume":"63","author":"Norberg","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0175","series-title":"Psychopharmacology: Fourth Generation of Progress","first-page":"787","article-title":"Animal models of psychiatric disorders","author":"Geyer","year":"1995"},{"key":"10.1016\/j.tips.2012.06.006_bib0180","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/7854_2010_57","article-title":"Models of neurodevelopmental abnormalities in schizophrenia","volume":"4","author":"Powell","year":"2010","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.tips.2012.06.006_bib0185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YCO.0b013e3283503637","article-title":"The role of the \u03b17 nicotinic receptor in cognitive processing of persons with schizophrenia","volume":"25","author":"AhnAllen","year":"2012","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0190","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.neuropharm.2011.11.008","article-title":"Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia","volume":"62","author":"Alberati","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.tips.2012.06.006_bib0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0963721410378359","article-title":"New opportunities in the treatment of cognitive impairments associated with schizophrenia","volume":"19","author":"Geyer","year":"2010","journal-title":"Curr. Dir. Psychol. Sci."},{"key":"10.1016\/j.tips.2012.06.006_bib0200","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1093\/schbul\/sbi041","article-title":"Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia","volume":"31","author":"Floresco","year":"2005","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.tips.2012.06.006_bib0205","series-title":"Ein kurzes Lehrbuch f\u00fcr Studirende und Aerzte","first-page":"435","year":"1893"},{"key":"10.1016\/j.tips.2012.06.006_bib0210","series-title":"Dementia Praecox, oder die Gruppe der Schizophrenien","year":"1911"},{"key":"10.1016\/j.tips.2012.06.006_bib0215","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.biopsych.2005.12.015","article-title":"Contextual and temporal modulation of extinction: behavioral and biological mechanisms","volume":"60","author":"Bouton","year":"2006","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0220","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.mp.4001939","article-title":"Mechanisms of fear extinction","volume":"12","author":"Myers","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tips.2012.06.006_bib0225","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.cell.2011.10.009","article-title":"Molecular mechanisms of fear learning and memory","volume":"147","author":"Johansen","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tips.2012.06.006_bib0230","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1146\/annurev.psych.121208.131631","article-title":"Fear extinction as a model for translational neuroscience: ten years of progress","volume":"63","author":"Milad","year":"2012","journal-title":"Annu. Rev. Psychol."},{"key":"10.1016\/j.tips.2012.06.006_bib0235","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.neuron.2005.09.025","article-title":"Contributions of the amygdala to emotion processing: from animal models to human behavior","volume":"48","author":"Phelps","year":"2005","journal-title":"Neuron"}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614712001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614712001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T13:10:24Z","timestamp":1642770624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614712001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0165614712001125"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2012.06.006","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}